Antidote Joins GodLike Esports Valorant Team

Godlike Esports Antidote

Sabyasachi ‘antidote’ Bose has been unveiled as the new player for Godlike Esports. He is the addition to the team as a 6th player. The ex-player of Velocity Esports (previously Team Mahi) entered into Valorant Esports on 27th July 2020.

Since then, the squad has dominated the complete Indian Valorant esports ecosystem. The former Team Mahi, consisting of Amaterasu, Rite2ace, Vibhor, Hellff, Antidote, Excali had an undefeatable run for more than 5 consecutive events.

After dominating the Indian Valorant esports for more than 8 long months, Antidote announced its departure from the team on 16th May 2021. Now, he is back with new teammates and is ready to rule over other teams. 

Today, Godlike Esports announced the addition of Antidote into their team through the official Instagram post. They wrote, ” GodLike eSports is going through a major makeover. And here we present our latest crown jewel ? @officialantidotecs #dilsegodlike”

GODLIKE ESPORTS NEW VALORANT ROSTER

  • Tejas ‘Rexy’ Kotian
  • Debanjan ‘Deathmaker’ Das
  • Nikhil ‘Flexx’ Govind
  • Shane ‘Whitehorse’ Kariwow
  • Vishal ‘Haivaan’ Sharma
  • Sabyasachi ‘Antidote’ Bose

Presently, the squad is led by Haivaan. Under his leadership, the team recently won Esportz Premier Series – Qualifier 2. With this win, the squad has qualified for the Esportz Premier Series main event which is scheduled to held in December 2021 as a LAN event.

Recently, Nodwin Gaming and Riot Games announced the launch of the VALORANT Conquerors Championship a qualifying tournament for the South Asian players. The teams would qualify for the APAC Last Chance Qualifiers as part of the 2021 VALORANT Champions Tour.

Before leaving Team Mahi, Antidote revealed the wish to change his role and become IGL for his team. With the VCC 2021 coming closer, we can soon see him leading his team towards victory and qualify for the Valorant Champions Tour 2021. We wish Antidote and his team ‘All the Best” for the coming events.